Update on the treatment of type 2 diabetes mellitus

被引:437
作者
Jose Marin-Penalver, Juan [1 ]
Martin-Timon, Iciar [1 ]
Sevillano-Collantes, Cristina [1 ]
Javier del Canizo-Gomez, Francisco [1 ]
机构
[1] Univ Complutense, Endocrinol Sect, Hosp Univ Infanta Leonor, Fac Med, Avda Gran Via Este 80, Madrid 28031, Spain
关键词
Type 2 diabetes mellitus; Treatment; Oral antidiabetic agents; Injectable antidiabetic agents; Older people; Renal impairment; Future treatments;
D O I
10.4239/wjd.v7.i17.354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifestyle changes. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on the characteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.
引用
收藏
页码:354 / 395
页数:42
相关论文
共 333 条
[1]  
Abe M, 2007, CLIN NEPHROL, V68, P287
[2]   Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice [J].
Abe, Masanori ;
Okada, Kazuyoshi ;
Soma, Masayoshi .
CURRENT DRUG METABOLISM, 2011, 12 (01) :57-69
[3]   Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis [J].
Abe, Masanori ;
Okada, Kazuyoshi ;
Maruyama, Takashi ;
Maruyama, Noriaki ;
Matsumoto, Koichi .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (02) :169-176
[4]   HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin [J].
Ahren, Bo ;
Johnson, Susan L. ;
Stewart, Murray ;
Cirkel, Deborah T. ;
Yang, Fred ;
Perry, Caroline ;
Feinglos, Mark N. .
DIABETES CARE, 2014, 37 (08) :2141-2148
[5]   LKB1-dependent signaling pathways [J].
Alessi, Dario R. ;
Sakamoto, Kei ;
Bayascas, Jose R. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :137-163
[6]   Hypoglycemia in Patients with Diabetes and Renal Disease [J].
Alsahli, Mazen ;
Gerich, John E. .
JOURNAL OF CLINICAL MEDICINE, 2015, 4 (05) :948-964
[7]   Minimizing Hypoglycemia in Diabetes [J].
Amiel, Stephanie A. ;
Aschner, Pablo ;
Childs, Belinda ;
Cryer, Philip E. ;
de Galan, Bastiaan ;
Heller, Simon R. ;
Frier, Brian M. ;
Gonder-Frederick, Linda ;
Jones, Timothy ;
Khunti, Kamlesh ;
Leiter, Lawrence A. ;
Luo, Yingying ;
Vigersky, Robert ;
Zoungas, Sophia .
DIABETES CARE, 2015, 38 (08) :1583-1591
[8]   Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].
Amori, Renee E. ;
Lau, Joseph ;
Pittas, Anastassios G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206
[9]   Current understanding of metformin effect on the control of hyperglycemia in diabetes [J].
An, Hongying ;
He, Ling .
JOURNAL OF ENDOCRINOLOGY, 2016, 228 (03) :R97-R106
[10]   Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial [J].
Andrews, R. C. ;
Cooper, A. R. ;
Montgomery, A. A. ;
Norcross, A. J. ;
Peters, T. J. ;
Sharp, D. J. ;
Jackson, N. ;
Fitzsimons, K. ;
Bright, J. ;
Coulman, K. ;
England, C. Y. ;
Gorton, J. ;
McLenaghan, A. ;
Paxton, E. ;
Polet, A. ;
Thompson, C. ;
Dayan, C. M. .
LANCET, 2011, 378 (9786) :129-139